Skip to content

Study · Animal study (in vivo) · rat · 2004

3 results

[An experimental substantiation for using the "Semax" neuroprotector in the treatment of optic-nerve diseases].

Sheremet NL, Polunin GS, Ovchinnikov AN, Kamenskiĭ AA, Levitskaia NG, Andreeva LA, Alfeeva LIu, Nagaev IIu

Vestnik oftalmologii1 Nov 2004Cited by 1 (Europe PMC)

PMID15678666 (opens in a new tab)PepBankPUB-15678666
Publisher pageAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Pharmacokinetics

    In rats, tritium-labeled semax actively penetrated into the brain and eyes after intranasal administration.

    In plain wordsIn rats, semax given through the nose reached the brain and eyes.

    Peptide
    Semax
    Outcome
    Not applicablePenetration into brain and eyes after intranasal administration
    Study

    ratn: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated · intranasalAs given in this study (rat).

    Source sentences

    Summary
    A series of experiments, involving a tritium-marked "Semax", showed that the peptide actively penetrates into the brain and eyes of experimental animals after its intranasal administration.
    1 context sentence
    Summary · context
    In order to substantiate the feasibility of using the "Semax" neuroprotector in the treatment of optic-nerve diseases its pharmacokinetics in the intranasal administration was studied in experiments with rats; besides, the physical-and-chemical properties of "Semax" were investigated to define the p…

Studies that did not test the peptide alone2

In this study, Semax was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Semax.

  1. 02LabNot a test of Semax aloneIn vitro (cell-free)Other

    In an electrophoresis study, the semax preparation did not disintegrate in the electric field.

    In plain wordsIn lab tests, semax did not break down in an electric field.

    Peptide
    Semax
    Outcome
    No significant changeStability in the electric field
    Study

    n: not reported in source

    Outcome group
    Formulation, delivery and stability · Pharmacology

    Source sentences

    Summary
    that the preparation does not disintegrate in the electric field, it posses the electrophoretic mobility and moves, in the electric field, from plus to minus; therefore, the "Semax" solution must be fed from anode while making the electrophoresis procedure.
    1 context sentence
    Summary · context
    In order to substantiate the feasibility of using the "Semax" neuroprotector in the treatment of optic-nerve diseases its pharmacokinetics in the intranasal administration was studied in experiments with rats; besides, the physical-and-chemical properties of "Semax" were investigated to define the p…

    In this study, Semax was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semax.

  2. 03LabNot a test of Semax aloneIn vitro (cell-free)Other

    In an electrophoresis study, semax had electrophoretic mobility and moved from plus to minus in the electric field.

    In plain wordsIn lab tests, semax moved in an electric field from the plus side to the minus side.

    Peptide
    Semax
    Outcome
    Not applicableElectrophoretic mobility
    Study

    n: not reported in source

    Outcome group
    Formulation, delivery and stability · Pharmacology

    Source sentences

    Summary
    it posses the electrophoretic mobility and moves, in the electric field, from plus to minus
    1 context sentence
    Summary · context
    In order to substantiate the feasibility of using the "Semax" neuroprotector in the treatment of optic-nerve diseases its pharmacokinetics in the intranasal administration was studied in experiments with rats; besides, the physical-and-chemical properties of "Semax" were investigated to define the p…

    In this study, Semax was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semax.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 17:28 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.